Study for advanced lung cancer with gene mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be willing and able to read the study and sign a consent form (dated).
- Be age 18 or older.
- Have stage IV non-small cell lung cancer confirmed by lab testing.
- Have a confirmed cancer gene mutation (such as EGFR, ALK, or ROS1) from an approved local lab.
- Be able to do daily activities with limited/no assistance (ECOG 0–1).
- Have health tests showing enough blood counts and organ function, and a predicted survival of at least 12 weeks.
- Have visible, measurable tumors on scans that can be tracked (measurable lesions per RECIST 1.1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This trial studies whether combining platinum chemotherapy with immune “checkpoint” medicine works better for people with stage IV lung cancer that has EGFR, ALK, or ROS1 mutations. It focuses on tumors that have grown again after first-line treatment.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This study tests whether using a blood test to detect leftover tumor DNA after surgery can guide extra treatment for people with EGFR-mutant lung cancer. The goal is to see if starting or avoiding targeted therapy based on this test improves outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.